Histologic and pathologic findings are the most common and useful prognostic factors in transitional cell cancer of the bladder. Thus, clinicians know their peculiar limits very well. The Authors report the results of a literature review about an oncogenic-derivative protein (p53) and about indices of proliferation Ki 67 and TLI, which are frequently studied in bladder cancer.
EsrigD., SpruckC.H.III, NicholsP.W., ChaiwunB., StevenK., GroshenS., ChenS.C., SkinnerD.G., JonesP.A., CoteR.J.: p53 nuclear protein accumulation correlates with mutations in p53 gene, tumour grade and stage in bladder cancer. Am. J. Pathol., 143: 1389–97, 1993.
2.
KerrJ.F.R., WinterfordCM., HarmonB.V.: Apoptosis. Its significance in cancer and cancer therapy. Cancer, 73: 2013–26, 1994.
3.
SoussiT., LegrosY., LubinR., OryK., SchlichtholzB.: Multifactorial analysis of p53 alteration in human cancer: a review. Int. J. Cancer, 57: 1–9, 1994.
4.
HabuchiT., OgawaO., KakehiY., OguraK., KoshibaM., SugiyamaT., YoshidaO.: Allelic loss of chromosome 17p in urothelial cancer: strong association with invasive phenotype. J. Urol., 148: 1595–1599, 1992.
5.
LunecJ., ChallenC., WrightC., MellonK., NealD.E.: c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder. The Lancet, 339: 439–40, 1992.
6.
WrightC., MellonK., JohnstonP., LaneD.P., HarrisA.L., HorneC.H.W., NealD.E.: Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br. J. Cancer, 63: 967–970, 1991.
7.
FujimotoK., YamadaY., OkajimaE., KakizoeT., SasakiH., SugimuraT., TeradaM.: Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Research, 52: 1393–1398, 1992.
8.
Ding-weiY., Jia-fuZ., Song-xiQ., Yong-jiangM.: Expression of p53 product in Chinese human bladder carcinoma. Urol. Res., 21: 223–226, 1993.
9.
SarkisS.A., DalbagniG., Cordon-CardoC., ZhangZ.F., SheinfeldJ., FairW.R., HerrH.W., ReuterV.E.: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer Inst., 85: 53–59, 1993.
10.
LipponenP.K.: Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int. J. Cancer, 53: 365–370, 1993.
11.
MochH., SauterG., MooreD., MihatschM.J., GudatF., WaldmanF.: p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch.-A. Pathol. Anat. Histopathol., 423: 329–34, 1993.
12.
Cordon-CardoC., DalbagniG., SaezG.T., OlivaM.R., ZhangZ.F., RosaiJ., ReuterV.E., PellicerA.: p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer, 56: 347–53, 1994.
13.
GardinerR.A., WalshV., AllenS., RahmanM.L.T.H., SamaratungaG.J., LavinS., LavinM.F.: Immunohistological expression of p53 in primary pTI transitional cell bladder cancer in relation to tumour progression. Br. J. Urol., 73: 526–32, 1994.
14.
ThomasD.J., RobinsonM.C., CharltonR., WilkinsonS., ShentonB.K., NealD.E.: p53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder. Br. J. Urol., 73: 533–37, 1993.
15.
MellonK., WilkinsonS., VickersJ., RobinsonM.C., ShentonB.K., NealD.E.: Abnormalities in p53 and DNA content in transitional cell carcinoma of the bladder. Br. J. Urol., 73: 522–25, 1994.
16.
TachibanaM., DeguchiN., BabaS., Jitsukawa, HataM., TazakiH.: Prognostic significance of Bromodeoxyuridine high labeled bladder cancer measured by flow cytometry: does flow cytometric determination predict the prognosis of patients with transitional cell carcinoma of the bladder. J. Urol., 149: 739–743, 1993.
17.
MellonK., NealD.E., RobinsonM.C., MarshC., WrightC.: Cell cycling in bladder carcinoma determined by monoclonal antibody Ki 67. Br. J. Urol., 66: 281–285, 1990.
18.
BushC., PriceP., NortonJ., ParkinsC.S., BaileyM.J., BoydJ., JonesC.R., A'HernR.P., HorwichA.: Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. Br. J. Cancer, 64: 357–360, 1991.
19.
TsujhashiH., NakanishiA., MatsudaH., UejimaS., KuritaT.: Cell proliferation of human bladder tumours determined by BrdUrd and Ki-67 immunostaining. J. Urol., 145: 846–849, 1991.
20.
FontanaD., BellinaM., GubettaL., FasolisG., RolleL., ScoffoneC., PorpigliaF., ColomboM., TarabuzziR., LeonardoE.: Monoclonal antibody Ki-67 in the study of the proliferative activity of bladder carcinoma. J. Urol., 148: 1149–1151, 1992.
21.
CohenM.B., WaldmanF.M., CarrolP.R., KerschmannR., ChewK., MayallB.H.: Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Hum. Pathol., 24: 772–778, 1993.
22.
StavropoulosN.E., Ioackim-VelogianniE., HastazerisK., KitsiouE., StefanakiS., AgnantisN.: Growth fractions in bladder cancer defined by Ki67: association with cancer grade, category and recurrence rate of superficial lesions. Br. J. Urol., 72: 736–39, 1993.
23.
ZambelliS., ZaninA., GaglioA., ZaiG., BoscoE., AndrionA., MagnaniC.: Ki-67 scores and AgNor counts in transitional cell carcinoma of the bladder: apparent lack of prognostic value. Arch. It. Urol., LXV: 665–70, 1993.
24.
BeniniE., CostaA., PizzocaroG., CampoB., MilaniA., TorelliT., VeneroniS., OrdesiG., PilottiS., SilvestriniR.: Biological markers in transuretral biopsies from bladder cancer: preliminary results. Int. J. Oncol., 3: 817–21, 1993.
25.
LipponenP.K., NordlingS., EskelinenM.J., JauhiainenK., TerhoR., HarjuE.: Flow cytometry in comparison with mitotic index in predicting disease outcome in transitional-cell bladder cancer. Int. J. Cancer, 53: 42–47, 1993.
26.
MeyerJ.S.: Growth and cell kinetic measurements in human tumours. Path. Ann., 16(part 2): 53, 1991.
27.
TachibanaM., DeguchiN., BabaS., JitsukawaS., HataM., TazakiH.: Multivariate analysis of flow cytometric deoxyribonucleic acid parameters and histological features for prognosis of bladder cancer patients. J. Urol., 146: 1530, 1991.
28.
SchapersR.F.M., JokeJ.P.Z., PauwelsR.P.E., SmeetsA.W.G.B., van den BrandtP.A., TankeH.J., BosmanF.T.: Image cytometric DNA analysis in transitional cell carcinoma of the bladder. Cancer, 72: 182–189, 1993.
29.
KiermeneyL.A.L.M., WitjesJ.A., HeijbroekR.P., VerbeekA.L.M., DebruyneF.M.: Predictability of recurrent and progressive disease in individual patients with superficial bladder cancer. J. Urol., 150: 60–64, 1993.
30.
LipponenP., EskelinenM.J., JauhiainenK..: Clinical prognostic factors in transitional cell cancer of the bladder. Urol. Int., 50: 192–197, 1993.
31.
ParmarM.K.B., FreedmanL.S., HargreaveT.B., TolleyD.A.: Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report for the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J. Urol., 142: 284–288, 1989.
32.
OomsE.C.M., AndersonW.A.D., AlonsC.L., BoonM.E., VeldhuizenR.W.: Analysis of the performance of pathologists in the grading of bladder tumours. Hum. Pathol., 14: 140–143, 1983.
TakashiM., MuraseT., MizunoS., HamajimaN., OhnoY.: Multivariate evaluation of prognostic determinants in bladder cancer patients. Urol. Int., 42: 368–364, 1987.
35.
CutlerS.J., HeneyN.M., FriedellG.H.: Longitudinal study of patients with bladder cancer. Factors associated with disease recurrence and progression. In: BonneyW.W., ProutG.R. (eds): Bladder cancer.Baltimore, Williams & Wilkins, AUA Monograph 1982, vol. 17, pp. 35–42.
36.
LutzeyerW., RübbenH., DahmH.: Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J. Urol., 127, 250–252, 1982.
37.
HeneyNm., AhmedS., FlanaganMj., FrableW., CorderM.P., HafermannM.D., HawkinsI.R. for “National Bladder Cancer Collaborative Group”: Superficial bladder cancer: progression and recurrence. J. Urol., 130: 1083–1086, 1983.
38.
SmithG., EltonR.A., BeynonL.L., NewsamJ.E., ChisholmG.D., HargreaveT.B.: Prognostic significance of biopsy results of normal-looking mucosa in cases of superficial bladder cancer. Br. J. Urol., 55: 665–669, 1983.
39.
LipponenP.K., CollanY., EskelinenM.J., PesonenE., SotarautaM.: Volume corrected mitotic index (M/V Index) in human bladder cancer: relation to histological grade (WHO), clinical stage (UICC) and prognosis. Scand. J. Urol. Nephrol., 24: 39–45, 1990.
HulandH., KloppelG., OttoU., DroeseM.: The value of histologic grading and staging, random biopsies, tumour and bladder mucosa blood groups antigens, in predicting progression of superficial bladder cancer. Eur. Urol., 10: 28–31, 1984.
